Clinical trial
Invaplex 50 Vaccine Dose-Ranging
NCT00082069 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00082069 |
|---|---|
| Title | Invaplex 50 Vaccine Dose-Ranging |
| Official title | Safety and Immunogenicity Study of an Intranasal Shigella Flexneri 2a Invaplex 50 Vaccine |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diarrhea |
| Intervention type | Biological |
| Interventions | Shigella flexneri 2a Invaplex 50 |
| Enrollment | 32 |
| Start date | Apr 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Apr 30, 2004 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: